Interfering with S100B-effector protein interactions for cancer therapy.
Drug Discov Today
; 25(9): 1754-1761, 2020 09.
Article
in En
| MEDLINE
| ID: mdl-32679172
S100 calcium-binding protein B (S100B) is overexpressed in various malignant tumors, where it regulates cancer cell proliferation and metabolism by physical interactions with other molecules. Interfering with S100B-effector protein interactions is a potential strategy to treat malignant tumors. Although some S100B inhibitors have been discovered by virtual screening (VS), most target the S100B-p53 interaction. Hence, there is scope for the discovery of other S100B-effector protein interaction modulators for malignant tumors. In this review, we provide an overview of S100B-effector protein interaction inhibitor discovery using VS and discuss promising S100B-effector protein interaction targets that permit in silico analysis for drug discovery.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
S100 Calcium Binding Protein beta Subunit
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Drug Discov Today
Journal subject:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Year:
2020
Document type:
Article
Affiliation country:
China
Country of publication:
Reino Unido